Wellness Shot
Dual-incretin weekly injections under physician supervision
Tirzepatide engages two incretin pathways rather than one. It is a prescription medication with substantial trial evidence, and like semaglutide it requires evaluation, titration and monitoring.
What's available
Package required. Call 469-466-1134 for discounted package pricing and to arrange your medical evaluation.
At a glance
A plain description of what is in the bag and what happens while you are here.
Tirzepatide agonises both GIP and GLP-1 receptors rather than GLP-1 alone.
SURMOUNT-1 reported the largest mean reductions seen in this drug class to date.
Dose is stepped up gradually, which is how the gastrointestinal effects are managed.
The science
We would rather tell you where the evidence is strong, where it is thin, and where it simply does not exist yet.
By engaging both incretin pathways, tirzepatide enhances glucose-dependent insulin secretion, slows gastric emptying and reduces appetite.
In adults with obesity or overweight without diabetes over 72 weeks, mean weight reduction was approximately 15.0%, 19.5% and 20.9% at 5mg, 10mg and 15mg weekly respectively, versus 3.1% for placebo on the treatment-regimen estimand. The efficacy estimand reported up to around 22.5% at the highest dose.
Nausea, vomiting, diarrhoea, constipation and reduced appetite, generally dose-dependent and most pronounced during titration.
Pancreatitis, gallbladder disease, and hypoglycaemia when combined with insulin or sulfonylureas. Beyond obesity, tirzepatide is also approved for type 2 diabetes and for obstructive sleep apnoea in obesity.
Who commonly considers this: Adults with obesity, or overweight with a weight-related comorbidity, following medical evaluation.
This button goes straight to the live calendar for this treatment — real availability, updated as appointments are taken. Prefer to talk it through first? Call us.
Visit us
The DRIPBaR Frisco
3311 Preston Rd, Ste 9, Frisco, Texas 75034
Tel: 469-466-1134
Zen Health PLLC · Physician: Dr. Aminidhan D. Thakkar, MD
